

1 Incidences of poor-quality pharmaceutical products in Nepal

2 Astha Neupane, Maheshwor Bastakoti, Sabita Tamang, Basant Giri*

3 Center for Analytical Sciences, Kathmandu Institute of Applied Sciences

4 P. O. Box 23002, Kathmandu, Nepal

5
6
7
8 *Correspondence

9 Dr. Basant Giri

10 bgiri@kias.org.np

11 12 **ABSTRACT**

13 Pharmaceutical products are used to treat, prevent, and save lives of millions of people globally.

14 However, pharmaceutical products known as substandard and falsified that do not meet

15 regulatory standards and quality threaten the health of the population of today and future leading

16 to socio-economic hardship, drug resistances and put life of patients in danger. We analyzed the

17 recall notice from 2010 to 2020 issued by the department of drug administration (DDA),

18 government of Nepal to understand the overview of substandard and falsified pharmaceutical

19 products in Nepal. The number of recalled pharmaceutical products has significantly increased

20 over the past decade in Nepal (p -value < 0.05). The most recalled drugs were antimicrobials

21 followed by gastrointestinal medicines, vitamins and supplements, pain and palliative medicines

22 among others. Number of recalled drugs manufactured by domestic pharmaceutical producers

23 and imported ones were not significantly different. Majority of imported recalled drugs

24 originated from India. Sixty-two percentage of recalled drugs were substandard, 11% were

25 falsified and remaining 27% were not registered at the DDA. Similarly, sixty percentage of

26 recalled drugs were modern and 35% were traditional ones. The hand sanitizers used to minimize

27 the COVID-19 transmission contributed significantly to the list of recalled pharmaceutical
28 products in 2020. Most of these sanitizers contained significant amount of methanol instead of
29 ethyl alcohol or isopropyl alcohol. We also reviewed peer-reviewed research papers that reported
30 data of substandard and falsified drugs. Only four such papers were found in literature. These
31 papers reported issues with labeling, unregistered drugs and drugs failed in a number of
32 laboratory testing. Since the recall data did not include number of samples tested and location of
33 sample collected, a systematic study to understand the prevalence of substandard and falsified
34 drugs in Nepal is recommended.

35

36 **Keywords:** Counterfeit drugs, falsified medical products, public health, substandard, fake drugs

37

Key questions

What is already known?

- Prevalence of substandard and falsified pharmaceutical products is a global threat to public health and socio-economy.

What are the new findings?

- We analyzed drug recall data from department of drug administration in Nepal and report that the substandard and falsified pharmaceutical products are increasing significantly.
- Antimicrobial drugs were the most frequently recalled drugs. Drugs manufactured by domestic producers and imported ones were equally recalled. Allopathic drugs were recalled more than ayurvedic products.

What do the new findings imply?

- This study suggested the problem of substandard and falsified pharmaceutical products is serious in Nepal. Integrated efforts from regulating agencies, manufacturers and pharmacies are recommended to minimize the circulation of such products in the country.

38
39
40
41
42
43

44 **Introduction**

45 Pharmaceutical products are essential products used to treat, prevent, and save lives of millions
46 of people globally¹. They should be safe, effective, and of good quality. Such products should be
47 prescribed and used rationally². However, pharmaceutical products that do not meet regulatory
48 standards and quality threaten the health of the population of today and future. Low-quality
49 drugs could lead to drug resistances and put life of patients in danger in addition to creating
50 economic and social burden to people³. There are several reasons for the circulation of such
51 substandard products in market such as lack of access to affordable, quality, safe and effective
52 medical products, and good governance, poor ethical practices in health care facilities and
53 medicine outlets. Limited technical capacity in manufacturing, quality control, and distribution
54 also contribute to the same problem⁴.

55 A recent meta-data analysis estimated that about 10.5% of the medicines worldwide are either
56 substandard or falsified. Prevalence of low-quality pharmaceutical products is higher in low- and
57 middle-income countries (13.6%) compared to high income countries. About 18.7% medicines
58 were estimated to be low-quality in Africa and 13.7% in Asia. The most substandard or falsified
59 drugs were the antimalarials (19.1%)³.

60 Nepal is one of the least developed countries that shares open and poorly regulated borders with
61 India and China. These two countries are considered as the major producers of low-quality and
62 fake pharmaceutical products circulating in the global market⁴. The domestic market for medical
63 products in Nepal was estimated to be 70 billion Nepal rupees in 2019 that included drugs (36
64 billion), raw materials and surgical equipment⁵. The department of drug administration (DDA),
65 which is the drug regulatory body of Nepal is responsible to authorize the distribution of all
66 pharmaceutical products. The DDA also aims to prevent the misuse or abuse of drugs and allied

67 pharmaceutical substances, the false or misleading information relating to the efficacy and use of
68 drugs and, to control the production, sale, distribution, export, import, storage and consumption
69 of those drugs which are not safe, efficacious, and of standard quality⁶. Few studies in past have
70 indicated the circulation of substandard, counterfeit, and unregistered drugs in the Nepali
71 market^{7,8,9}. The DDA Nepal recalls marketed drugs if the drugs do not fulfill any requirement as
72 indicated in the drug act 2035 B.S.⁶. It then issues public alerts and warnings when substandard,
73 falsified and unregistered medicine incidents are detected.

74 In this study, we analyzed the incidences of poor-quality drugs in Nepal. We used drug recall
75 notice issued by the DDA and research publications. We analyzed temporal trend of low-quality
76 drugs, types of drugs and formulations. We report the low-quality drugs have increased
77 significantly in Nepal that over the last decade and among them antimicrobials are the most
78 commonly found low-quality drugs.

79 **Methodology**

80 We carefully analyzed drug recall notice published by DDA Nepal from 2010 to 2020. The DDA
81 publishes such notices in its bulletins, websites and newspapers. We extracted important
82 information provided on the recall notice such as brand name, dosage form, batch number,
83 manufacturing date, expiry date, recall date, reason of non-compliance, and the manufacturer
84 information. We used National List of Essential Medicines 2016 of Nepal to classify the recalled
85 drugs into essential and non-essential drugs¹⁰. We used the WHO definition to identify
86 substandard, falsified and unregistered drugs¹¹. According to WHO definition, the substandard
87 drugs are authorized medical products but fail to meet quality standards or specifications or both.
88 Similarly, falsified drugs are medical products that misrepresent their identity, composition or
89 source¹². Pharmaceutical products that did not pass dissolution test, API assay, microbial test,


90 leakage test, friability, non-compliance with pharmacopeia, physical appearance, fungal count,
91 weight variation, particulate matter test, uniformity test, disintegration test, and pH test were put
92 together under substandard category. Similarly drugs that contained impurities, active ingredient
93 not meant to be there, had price sticker without approval, and did not have product specification
94 were classified as falsified pharmaceutical products. The drugs that were recalled because they
95 were not registered at DDA Nepal were classified under unregistered category. Unregistered
96 drugs do not undergo evaluation and/or approval by DDA Nepal. We classified the drugs as
97 “others” if the reason of recall was not specified.

98 In addition to recall notice, we also analyzed peer reviewed research articles from electronic
99 databases such as PubMed (2010-2020), Web of Science (2010-2020), Springer link (2010-
100 2020), and Google Scholar (2010-2020). We used the following search terms in conjunction with
101 Boolean search term (“OR”, “AND”) to identify related articles: “counterfeit*”, “substandard*”,
102 “falsified*”, “fake”, “spurious”, “unregulated drugs”, “unregistered”, or “frauds”; combined with
103 “Drug”, “medicine”, or “pharmaceutical”; “Nepal*”. In Google Scholar same search term was
104 used, but instead of “Nepal*”, we used “intitle:Nepal”. The articles were screened and evaluated
105 manually through the title and abstract on the basis of inclusion criteria: date of publication
106 (2010-2020), the language (English) in which the article was published, the article should
107 contain data/information on the prevalence of falsified/spurious/counterfeit/substandard drugs
108 and the location of experiment/research carried out. Similarly, the articles which did not meet
109 inclusion criteria were excluded. We also did not include opinion articles, letters, notes,
110 conference papers, book chapters, editorials or comments or articles with no abstracts or articles
111 with counterfeit or substandard medicines related to animals.

112 Statistical analyses of data such as Chi-square test, Fisher exact test and simple linear regression
113 were performed using R version 1.4.1106.

114 Results

115
116 We analyzed recalled drugs during 2010 – 2020. During this period 346 pharmaceutical products
117 were recalled by DDA Nepal. The number of recalled low-quality drugs in Nepal has
118 significantly increased in the last decade (figure 1A, linear regression, p value < 0.05, adjusted R-
119 squared value = 0.335). We found that only one pharmaceutical product was recalled in 2010.
120 The product was the lactate solution which is commonly used for fluid resuscitation. The lactate
121 was recalled from Nepali market since it did not pass the sterility test. There was no recall in
122 2012. The year of 2018 had the highest number of pharmaceutical products recalled (123
123 products, see figure 1a). Forty-six products were recalled in the year 2020, majority of which
124 were hand sanitizers. The recalled pharmaceutical products were from 96 manufacturers mostly
125 from Nepal and India, few from Bangladesh, and China. Manufacturer of 91 recalled drugs were
126 unknown.



127
128 **Figure 1:** (A) Temporal trend of recalled pharmaceutical products in Nepal. (B) Contribution of
129 different category of pharmaceutical products in the recall list.

130 Sixty percentage (n=346) of recalled pharmaceutical products were modern or allopathic (208)
131 and 35% were traditional or ayurvedic (120) (figure 1B). Two-sided fisher exact test showed that
132 significantly large number of modern pharmaceutical products were recalled (p-value< 0.001).
133 Twenty-seven percentage of the recalled drugs were unregistered at the DDA indicating they
134 were not authorized to distribute and sell in Nepal. Similarly, twenty percentage of the recalled
135 drugs, mostly allopathic, were listed as essential medicines and have been distributed free of cost
136 through government health centers. Remaining 40% were non-essential ones (p-value < 0.01)
137 and equal number of drugs were categorized as others, mostly ayurvedic since such drugs are not
138 classified as essential or non-essential. Most of the recalled pharmaceutical products were
139 substandard (215) followed by unregistered (93) and falsified (38) (see figure 1B). We found that
140 the recall pattern among these three categories were significantly different (one-way chi-square
141 test, p-value < 0.001, X-squared = 118.66, df = 2). The recalled pharmaceutical products
142 included a significantly (two-sided fisher exact test, p-value <0.05) higher number of
143 domestically manufactured (134) items than the imported (107) ones which were manufactured
144 mostly in India (figure 1B). Few drugs from Bangladesh and China were also recalled. Country
145 of origin of 105 recalled pharmaceutical products were not identified.





Figure 2: (A) Different categories of recalled drugs based on their therapeutics, (B) List of major reasons for recalling pharmaceutical products, (C) Types of dosage forms of recalled drugs, (D) Self life of recalled pharmaceutical products after the recall (in months).

146 Based on the generic names of each non-ayurvedic pharmaceutical product, we identified their
 147 generic names and then categorized them into different groups based on their therapeutic
 148 properties. The top 10 most recalled drugs belonged to antimicrobials (46) followed by
 149 gastrointestinal medicines (35), vitamins and minerals (29), antiseptic (23), hormones and
 150 contraceptives (18), and pain and palliative care medicines (16), fluid and electrolyte
 151 replenishment (13), cardiovascular and renal drugs (7), anti-diabetes (5) and antihistamines (5)
 152 (see figure 2A). Remaining recalled drugs were CNS drugs, respiratory system drugs,
 153 prostaglandin analogues, antirheumatic. Nineteen drugs were not classified into any of those and
 154 labeled as “others” since not enough information was available. The DDA provided reason(s) for

155 every recalled pharmaceutical product. Most of the drugs were recalled because they were not
156 registered (93) at DDA. The most common reason for recall among registered drugs was the
157 failure to comply with microbial test (82) followed by failures in dissolution test (40), in
158 quantitative assay for active pharmaceutical ingredient (21), and in physical characteristics (17).
159 Eleven products did not comply label requirements and 12 had one or more impurity. others (see
160 figure 2B). Tablets were the most recalled dosages form followed by powder, solution, capsules,
161 syrups/suspension, cream/ointment and other (figure 2C). The shelf-life of recalled drugs ranged
162 from less than three months (16.4%) to more than two years at the time of recall (figure 2D).

163 **Low-quality drugs reported in research papers**



173 Figure 3: Flow chart of research papers search procedure

174 We also systematically looked into published research works in order to find the reporting of
175 low-quality drugs in Nepali market. Initially, we identified 467 journal articles through the
176 literature search in four different databases: PubMed, Springer link, Web of science and Google
177 scholar. We removed 13 duplicate articles and brought the number of articles to 454. By

178 screening the title and abstract of these articles, we removed 439 articles and we considered only
179 15 in next step. We read the full text of these articles and excluded 11 articles because they did
180 not follow the inclusion criteria. At last, four articles were found to be relevant that contained
181 primary information on the prevalence of substandard, falsified, and unregistered medicines in
182 the Nepali market (list is given in supplementary information). The flow chart of the study is
183 given in a flow chart in figure 3.

184 A cross sectional descriptive study reported by Jha et al.¹³ assessed the quality of essential
185 medicines available in public health care facilities of Nepal. The study was carried out in 62
186 health facilities in 21 districts of Nepal representing all seven provinces. Out of 244 batches of
187 20 different generics of essential medicines tested, 37 batches failed to meet the required
188 pharmacopeial standards which constitute 62.16% batches of medicines supplied by Government
189 of Nepal and 37.83% batches purchased from local resources. The failed medicines included
190 antibiotics, supplements, anti-diabetics etc. Providing required information on the label is
191 another issue. Majority of the pharmaceutical products inspected in Chitwan in 2017 involving
192 759 drugs from 37 Nepali pharmaceutical companies did not meet the regulatory standards of
193 primary labeling⁸. Most of them missed at least one critical information on the label such as drug
194 quantity, name of pharmacopoeia, serial number of pharmaceutical industries, price list, drug
195 classification, and information in Nepali language. Majority of the products (84%) did not
196 provide the directions of use. Similarly 90% of drug samples (n=40) in Kathmandu did not
197 comply with the existing regulatory requirement on labeling and 42.5% brands did not mention
198 about the pharmacopoeial standard⁷. The same study showed that 40% of domestic and 28%
199 imported brands failed to meet national criteria during laboratory analysis. In average 32.5%
200 samples were found to be of substandard quality in this study. This study aims to evaluate the

201 availability and rationality of unregistered fixed-dose drug combinations (FDCs) in Nepal. A
202 snowball sampling method with visits to 20 retail pharmacies in each of five major cities in
203 Nepal was used to assess the availability of unregistered FDCs. To justify the rationality of the
204 FDCs obtained from these five cities, the toolkit developed by Health Action International Asia-
205 Pacific (HAI-AP) was used. Forty-one unregistered fixed-dose drug combinations were found in
206 five major cities of Nepal, majority of which were anti-inflammatory/analgesic/antipyretics.
207 Regulatory authorities should initiate strict monitoring and appropriate regulatory mechanisms to
208 prohibit the use of unregistered and irrational FDCs.⁹

209 **Discussion**

210
211 The low quality medicines are recalled from the market by manufacturing company voluntarily
212 or by the order of national or international drug regulatory bodies to protect the public from a
213 defective or potentially harmful product¹⁴. Many recall incidents of poor quality medicine have
214 been reported globally¹⁵. In 2010, Johnson and Johnson recalled the drug which was deviated
215 from good manufacturing practices (GMPs). Similarly, in 2012, the US FDA recalled the
216 contaminated vials of corticosteroid medication which was manufactured by the New England
217 Compounding Center¹⁶.

218 The overall trend of recalled drugs is increasing in Nepal. Starting from a single drug recall in
219 2010 to highest numbers (123) in 2018. In this year, most of the drugs (90) were recalled since
220 they were not registered with the DDA. This indicates that the circulation of unregistered drugs
221 is a serious issue in Nepal which may be contributed by the open and unregulated boarder with
222 India. Both allopathic and ayurvedic medicines are widely used in Nepal. The allopathic
223 medicines are the modern medicines that are manufactured synthetically whereas ayurvedic
224 medicines are the traditional medicines which uses the natural remedies to improve health or to

225 treat diseases. Both types of medicines are commercially manufactured in Nepal in addition to be
226 imported mostly from India. There are two groups of manufacturers of ayurvedic drugs in Nepal.
227 Mostly they are manufactured by registered commercial companies and sold in market in
228 packages through registered shops. The ayurvedic drugs are also manufactured by individuals or
229 small business holders who may not be registered at DDA. They sell their ayurvedic products in
230 streets, through door-to-door service, and through individual networks. We found that both
231 allopathic and ayurveda medicines were recalled due to their non-compliance with government
232 standards. Ayurvedic medicines are utilized prominently in Nepalese communities, and
233 sometimes, there are used concomitantly with allopathic¹⁷. There has been an increasing interest
234 in the study of traditional medicine in different parts of world¹⁸. However, there is the lack of
235 quality research and standards, and stringent regulatory environment in this sector. Hence, the
236 successful implementation of herbal pharmacovigilance, GMP as well as inspection on herbal
237 medicine formulation is essential for developing reliable information on the safety of ayurveda
238 medicines¹⁷.

239 Essential medicines are defined by WHO as the medicines that satisfy the priority healthcare
240 needs of the population. In Nepal, the concept of Essential medicines was adopted in 1986 A.D
241 to enhance the access of essential medicines to every individual. The main criteria for selection
242 of the medicines in the National List of Essential Medicine (NLEM) are public health relevance,
243 efficacy, safety, cost-effectiveness and access of the drugs. The NLEM 2016 of Nepal contains
244 359 medicines which has 86 medicines more than the NLEM 2011¹⁰. Following criteria were
245 used for including a medicine in NLEM: approved and licensed in Nepal, relevance to a disease
246 posing public health problem, proven efficacy and safety, aligned with standard treatment
247 guideline of Nepal, stable under storage conditions, cost-effectiveness, access. However in

248 following conditions medicines were excluded from the NLEM list: banned in Nepal, safety
249 concerns, if medicine with higher efficiency, safety profile and lower-cost is available, irrelevant
250 to public health disease burden, antimicrobial resistant, medicine with abuse and misuse
251 potential¹⁰. Our study shows that some of the recalled allopathic medicines also listed under
252 National essential drug list by the Government of Nepal. Jha et.al¹⁹ indicated the presence of
253 high number of substandard essential medicine and majority of which were purchased by
254 Government of Nepal. Essential medicines for various illnesses are supplied free of cost in Nepal
255 through government hospitals, health care centers and health posts. Poor quality of essential
256 medicines can have serious impact on public health. As significant proportion of drugs recalled
257 by DDA included essential medicines distributed by Government of Nepal, there is enough room
258 to improve the procurement procedure and upgrading of health facilities of Nepal that store and
259 distribute the medicines. In one study²⁰ that looked into the procurement practices in Nepal
260 reported that the majority of hospital pharmacies in Nepal use an expensive direct-procurement
261 model for purchasing medicines. They relied on on doctors' prescriptions to choose a particular
262 brand, which may be influenced by pharmaceutical companies' marketing strategies. Most of the
263 hospital pharmacies procured only registered medicines, a minority reported purchasing
264 unregistered medicines through unauthorised supply-chains. Not all pharmacies followed Basel
265 Statements during procurement of medicines. Such pharmacies may need awareness and training
266 to fully adopt regulation of national and international policies for enhancing accessibility to
267 quality medicines.

268 Among the recalled group, antimicrobial group of medicines had the highest frequency of
269 incidents. Acharya et.al²¹ highlighted the problem of antimicrobial resistance in Nepal as an
270 alarm bell for an even worse public health situation. Suboptimal dose or poorly manufactured

271 antibiotic medicine increases the chance of antimicrobial resistance which is an emerging health
272 menace in current situation²². Most of the recalled therapeutic categories of medicines like
273 vitamins and minerals, NSAID, antipyretic and analgesic, antiseptic, fluid and electrolyte
274 replenishment and others are over-the-counter medicine that can be brought from the pharmacy
275 without the prescriptions and such medicines can pose a significant threat to the groups of
276 patients who consume them²³. Similarly, few antidiabetes medicines were also recalled.
277 Consumption of such medicines will increase the incidence of macrovascular and microvascular
278 complications due to compromised glucose control²⁴.

279 Our study shows that the drugs were recalled due failure in various laboratory tests like assay,
280 content uniformity test, weight variation, impurity test, dissolution test, friability test,
281 identification and sterility test. This phenomenon might be attributed to the lack of proper quality
282 control during manufacturing and lack of following proper procedures for transportation and
283 storage conditions¹². Jha et.al pointed out that recommended range for medicine storage in some
284 selected health facilities in Nepal was highly ignored¹⁹. Keeping the temperature and humidity
285 within a range is must necessary because it has a major role in degradation of medicines.
286 Another reason was failure to comply with the claim and incorrect labeling. The DDA regulation
287 requires appropriate labeling of marketed medicines to ensure patient medication safety, which
288 seems to be not followed properly. Thus, the drug analyst and the drug regulators should be
289 encouraged to remain vigilant about counterfeiting possibility and conduct the analysis including
290 chemical, physical, package inspection, and authentication efforts to determine quality more
291 accurately²⁵.

292 Domestically produced and imported medicines in Nepal should have the registration license
293 from DDA⁶. Nonetheless, we found that numbers of unregistered drugs were recalled during the

294 inspection. The drug supplier, whole seller, and retailers should ensure that the drug is registered
295 within the national regulatory body to timely identify substandard products before they reach
296 patients. Also, the regulatory body should stringent post-market surveillance to ameliorate the
297 situation. The unregistered medical products in Nepal may or may not have been registered in
298 India. Since Nepal shares open and poorly regulated boarder with India, drugs registered in India
299 are also easily sold in Nepali market. We found that nearly half of the total recalled medicines
300 were imported from India. India is the leading country in counterfeit drug production, having as
301 much as 35% of the world production originating within its borders²⁶.

302 One of the main reasons for the circulation of low-quality drugs in low-income countries is the
303 improper storage and transportation conditions. One study indicated only 13% of health facilities
304 (n=62) were found to follow the medicine storage guidelines in Nepal regarding sunlight
305 protection, humidity protection, heat protection and maintenance of ventilation¹³.

306 **COVID-19 related recalls**

307 The COVID-19 pandemic has resulted in the surge of substandard and falsified medical products
308 including drugs, masks, sanitizers, diagnostic tests and vaccines not just only related to COVID-
309 19 but other essential medical products²⁷. Rampant circulation of fake medical products during
310 emergencies has happened throughout the history²⁷. Counterfeit respirators and masks pose
311 additional risk to health care workers²⁸. Falsified chloroquine was seized in Cameroon, Congo
312 and Niger during March and May 2020. Chloroquine was controversially announced as the drug
313 for the treatment of COVID-19²⁹. Similarly, in 2019, with an outbreak of Covid-19 pandemic,
314 the FDA has uncovered nearly 1,300 fraudulent products³⁰. With the outbreak of Covid-19, in
315 March 2020, DDA Nepal has amended the standard for Instant Hand Sanitizer in order to
316 prohibit the selling of the substandard, falsified and unregistered sanitizers³¹. In between

317 September and November 2020, the DDA issued the recalled notice for 19 hand sanitizers which
318 failed to comply with the standard guideline. Some sanitizers were found to contain methanol,
319 rather than ethyl alcohol and isopropyl alcohol. As methanol is very toxic, some of the case
320 series indicated use of hand sanitizer containing methanol causes the transdermal absorption and
321 increases the risk of systemic toxicity³². The increase in the demand of hand sanitizer and other
322 medicines has increased the growth of e-commerce. Online sale of pharmaceutical products has
323 just started in Nepal during recent years. WHO has reported that 60% of medications purchased
324 through Internet could be counterfeit or substandard, and more than 50% of medications
325 purchased online from sites that concealed their actual physical address was found to be low
326 quality medicine³³. Nepali regulating agencies should pay special attention to this new method of
327 business in Nepal to protect people from the consumption of low-quality and fake medical
328 products. Inexorable growth of online pharmacies, unregulated websites, and, social media
329 platform for business may contribute to the dispensing of unapproved, subpotent, counterfeit,
330 expired or illegal drugs, and prescription drugs without a valid prescription in Nepal too³⁴.

331 **Conclusion**

332 In this paper we presented a detailed analysis of low-quality and fake drugs circulating in Nepal
333 in the past decade using recall notice of DDA Nepal. We showed that the number of recalled
334 drugs has significantly increased. This might be attributed to greater surveillance by DDA or the
335 substandard, falsified and unregistered medicine in the market are actually increasing. Similar to
336 global trend, antimicrobial drugs were the most recalled drugs in Nepal. Since antibiotics are
337 available over the counter in Nepal without doctor's prescription, it is necessary to enforce strict
338 regulation so that the rampant (mis)use of such drugs is minimized and prevent antibiotic
339 resistance. We relied on recall notice from DDA. The recall notice does not provide information

340 on the number of samples collected for testing and location of sample collection. Therefore, our
341 analysis did not report the rate or prevalence of low-quality drugs. Since sample collection
342 locations were not available, it was not possible to know the most vulnerable regions of Nepal
343 for low-quality drugs. Therefore, a systematic study is needed to understand the prevalence of
344 substandard and falsified drugs in Nepal covering different parts of the country on regular basis.
345 We suggest having more stringent regulatory systems and implementation for pharmaceutical
346 manufacturing industries and post marketing surveillance.

347

348

349 **References**

- 350 1. Seiter, A. Health and Economic Consequences of Counterfeit Drugs. *Clin. Pharmacol. Ther.* **85**, 576–578 (2009).
- 351 2. WHO | Pharmaceutical products. *WHO* http://www.who.int/topics/pharmaceutical_products/en/.
- 352 3. Ozawa, S. *et al.* Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-
353 Income Countries: A Systematic Review and Meta-analysis. *JAMA Netw. Open* **1**, e181662 (2018).
- 354 4. OECD & European Union Intellectual Property Office. *Trade in Counterfeit Pharmaceutical Products*. (OECD, 2020).
355 doi:10.1787/a7c7e054-en.
- 356 5. Setopati. Domestic medicine market expanding. <https://en.setopati.com/market/126366/>.
- 357 6. DDA: Drugs Act 2035. <https://www.dda.gov.np/content/drugs-act-2035>.
- 358 7. Gyanwali, P. *et al.* Surveillance of Quality of Medicines Available in the Nepalese Market: A Study from Kathmandu Valley. *J.*
359 *Nepal Health Res. Counc.* **13**, 233–240 (2015).
- 360 8. Poudel, R. S., Shrestha, S., Thapa, S., Poudel, B. K. & Chhetri, M. Assessment of primary labeling of medicines manufactured
361 by Nepalese pharmaceutical industries. *J. Pharm. Policy Pract.* **11**, 13 (2018).
- 362 9. Poudel, A., Mohamed Ibrahim, M. I., Mishra, P. & Palaian, S. Assessment of the availability and rationality of unregistered
363 fixed dose drug combinations in Nepal: a multicenter cross-sectional study. *Glob. Health Res. Policy* **2**, 14 (2017).
- 364 10. DDA: Essential Drug List. <https://www.dda.gov.np/content/essential-drug-list>.
- 365 11. Substandard and falsified medical products. [https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-](https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products)
366 [medical-products](https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products).
- 367 12. WHO | WHO Global Surveillance and Monitoring System for substandard and falsified medical products. *WHO*
368 <http://www.who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/>.
- 369 13. Jha, A. K. *et al.* *Quality of essential medicines in public health care facilities of Nepal–2019*. (2019).
- 370 14. Research, C. for D. E. and. Drug Recalls. *FDA* <https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls> (2019).
- 371 15. Nagaich, U. & Sadhna, D. Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history. *Int.*
372 *J. Pharm. Investig.* **5**, 13–19 (2015).
- 373 16. Hall, K., Stewart, T., Chang, J. & Freeman, M. K. Characteristics of FDA drug recalls: A 30-month analysis. *Am. J. Health-Syst.*
374 *Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm.* **73**, 235–240 (2016).
- 375 17. Shrestha, S., Danekhu, K., Sapkota, B., Jha, N. & Kc, B. Herbal pharmacovigilance in Nepal: challenges and recommendations.
376 *F1000Research* **9**, 111 (2020).

- 377 18. WHO. WHO global report on traditional and complementary medicine 2019. [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/978924151536)
378 [redirect/978924151536](https://www.who.int/publications-detail-redirect/978924151536).
- 379 19. Jha, A. K. *et al.* *Quality of essential medicines in public health care facilities of Nepal – 2019*.
380 <http://library.nhrc.org.np:8080/nhrc/handle/123456789/801> (2019).
- 381 20. Shrestha, M., Moles, R., Ranjit, E. & Char, B. Medicine procurement in hospital pharmacies of Nepal: A qualitative study
382 based on the Basel Statements. *PLoS One* **13**, e0191778 (2018).
- 383 21. Acharya, K. P. & Wilson, R. T. Antimicrobial Resistance in Nepal. *Front. Med.* **6**, 105 (2019).
- 384 22. Kelesidis, T. & Falagas, M. E. Substandard/counterfeit antimicrobial drugs. *Clin. Microbiol. Rev.* **28**, 443–464 (2015).
- 385 23. Rojas-Cortés, R. Substandard, falsified and unregistered medicines in Latin America, 2017-2018. *Rev. Panam. Salud Publica*
386 *Pan Am. J. Public Health* **44**, e125 (2020).
- 387 24. Saraswati, K., Sichanh, C., Newton, P. N. & Caillet, C. Quality of medical products for diabetes management: a systematic
388 review. *BMJ Glob. Health* **4**, e001636 (2019).
- 389 25. Alghannam, A., Aslanpour, Z., Evans, S. & Schifano, F. A systematic review of counterfeit and substandard medicines in field
390 quality surveys. *Integr. Pharm. Res. Pract.* **3**, 71–88 (2014).
- 391 26. Wertheimer, A. I. & Santella, T. M. Counterfeit drugs: defining the problem and finding solutions. *Expert Opin. Drug Saf.* **4**,
392 619–622 (2005).
- 393 27. Newton, P. N. *et al.* COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. *Lancet Glob. Health* **8**, e754–
394 e755 (2020).
- 395 28. Ippolito, M., Gregoret, C., Cortegiani, A. & Iozzo, P. Counterfeit filtering facepiece respirators are posing an additional risk
396 to health care workers during COVID-19 pandemic. *Am. J. Infect. Control* **48**, 853–854 (2020).
- 397 29. Waffo Tchounga, C. A. *et al.* Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19
398 pandemic. *J. Pharm. Biomed. Anal.* **194**, 113761 (2021).
- 399 30. McMeekin, J. National Consumer Protection Week: FDA Is Vigilant in Protecting Consumers Against COVID-19 Vaccine
400 Scams. *FDA* (2021).
- 401 31. DDA. DDA: Instant Hand Sanitizer (Alcohol Based) □□□□□□□□ □□□□□□□□ □□□□□ □□□□□. (2020).
- 402 32. Chan, A. P. L. & Chan, T. Y. K. Methanol as an Unlisted Ingredient in Supposedly Alcohol-Based Hand Rub Can Pose Serious
403 Health Risk. *Int. J. Environ. Res. Public Health* **15**, (2018).

- 404 33. Ashames, A., Bhandare, R., Zain AlAbdin, S., Alhalabi, T. & Jassem, F. Public Perception toward E-commerce of Medicines
405 and Comparative Pharmaceutical Quality Assessment Study of Two Different Products of Furosemide Tablets from
406 Community and Illicit Online Pharmacies. *J. Pharm. Bioallied Sci.* **11**, 284–291 (2019).
- 407 34. Fung, C. H., Woo, H. E. & Asch, S. M. Controversies and legal issues of prescribing and dispensing medications using the
408 Internet. *Mayo Clin. Proc.* **79**, 188–194 (2004).
- 409